Fresenius Medical Care is trading at $23.83, up +7.25%, after hours. - The increase follows the U.S. launch of its multiFiltratePRO system, the first FDA-cleared continuous kidney replacement therapy (CKRT) system for on-label regional citrate anticoagulation. - The FDA clearance for the system and its dedicated solutions was received on October 19, 2026. - The supplied price context shows a regular-session close of $22.22.